US2011172400A1PendingUtilityA1

Compositions monovalent for cd40l binding and methods of use

54
Assignee: DOMANTIS LTDPriority: Sep 17, 2004Filed: Nov 8, 2010Published: Jul 14, 2011
Est. expirySep 17, 2024(expired)· nominal 20-yr term from priority
A61P 3/10A61P 37/06A61P 37/00A61P 25/00A61P 29/00A61P 19/02C07K 2317/565C07K 2317/569C07K 16/2875C07K 2317/76C07K 16/28
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to antibody polypeptides that monovalently bind CD4OL. Antibody polypeptides that are monovalent for binding of CD4OL can inhibit CD4OL activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC4OL. in one aspect, a monovalent anti-CD4OL antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC4OL, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD4OL antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD4OL interactions in an individual and methods of treating diseases or disorders involving CD40/DC4OL interactions, the methods involving administering a monovalent anti-CD4OL antibody polypeptide to the individual.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody single variable domain polypeptide comprising CDR1-3, wherein said isolated antibody single variable domain specifically binds CD40L.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.